Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial

Lancet

Volumn 361, Issue 9356, 2003, Pages 449-456

  Calverley, Peter ^a   Pauwels, Romain ^b   Vestbo, Jørgen ^c   Jones, Paul ^d   Pride, Neil ^d   Gulsvik, Amund ^e   Anderson, Julie ^f   Maden, Claire ^f  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c HVIDOVRE HOSPITAL   (Denmark)

^d ST GEORGE S HOSPITAL   (United Kingdom)

^e National Lung and Heart Institute ^*  (Norway)

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE; SALMETEROL;

ADULT; AGED; ARTICLE; BREATHING DISORDER; CANDIDIASIS; CAPILLARY RESISTANCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG TOLERABILITY; EMERGENCY TREATMENT; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HEALTH STATUS; HOARSENESS; HUMAN; HYDROCORTISONE BLOOD LEVEL; LONG TERM CARE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MOUTH INFLAMMATION; NAUSEA; OROPHARYNX; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SYMPTOM; TREATMENT OUTCOME; TREMOR; VERTIGO; VOMITING;

EID: 0037425745     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12459-2     Document Type: Article

References (33)

1. Guidelines for the management of chronic obstructive pulmonary disease. Thorax. 52:1997;S1-S28.
2. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am J Respir Crit Care Med. 152:1995;S77-S120.
3. Jones P., Quirk F., Baveystock C., Littlejohns P. A self-complete measure of health status for chronic airflow limitation. Am Rev Respir Dis. 145:1992;1321-1327.
4. Seemungal T., Donaldson G., Paul E., Bestall J., Jeffries D., Wedzicha J. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 157:1998;1418-1422.
5. Siafakas N., Vermeire P., Pride N., et al. for the European Respiratory Society Tak Force. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J. 8:1995;1398-1420.
6. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: NHLBI/WHO Workshop Report, NIH publication 2701.Bethesda: US Department of Health and Human Services, 2001.
7. Rennard S, Anderson W, ZuWallack K, et al. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1087-92.
8. Boyd G., Morice A., Pounsford J., Sibert M., Peslis N., Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J. 10:1997;815-821.
9. Mahler D., Donohue J., Barbee R., et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 115:1999;957-965.
10. Taccola M., Bancalari L., Ghignoni G., Paggiaro P. Salmeterol versus slow-release theophylline in patients with reversible obstructive pulmonary disease. Monaldi Arch Chest Dis. 54:1999;302-306.
11. Di Lorenzo G., Morici G., Drago A., et al. for the SLMT02 Italian Study Group. Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease. Clin Ther. 20:1998;1130-1148.
12. Jones P., Bosh T. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 155:1997;1283-1289.
13. Dahl R., Greefhorst L., Nowark D., et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 164:2001;778-784.
14. Rossi A., Kristufek P., Levine B., et al. Formoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II Study Group: comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest. 121:2002;1058-1069.
15. Johnson M., Rennard S. Alternative mechanisms for long-acting beta2-adrenergic agonists in COPD. Chest. 120:2001;258-270.
16. Barnes P. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 161:2000;342-344.
17. Burge P., Calverley P., Jones P., Spencer S., Anderson J., Maslen T. Randomised, double-blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 320:2000;1297-1303.
18. Paggiaro P., Dahle R., Bakran I., Frith L., Hollingworth K. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet. 351:1998;773-780.
19. Pauwels R., Lofdahl C., Laitinen L., Schouten J., Postma D., Pride N., Ohlsson S. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking: the European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 340:1999;1948-1953.
20. Vestbo J., Sorensen T., Lange P., Brix A., Torre P., Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 353:1999;1819-1823.
21. Quanjer P., Tammeling G., Cotes J., Pedersen O., Peslin R., Yernault J. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European Community for Steel and Coal: official statement of the European Respiratory Society. Eur Respir J. 16:1993;5-40.
22. Brown H., Prescot R. Applied mixed models in medicine. Barnett V. Repeated measures data. 1st edn:1999;199-259 J Wiley and Sons, Chichester.
23. van Elteren P. On the combination of independent two-sample tests of Wilcoxon. Bull Int Statist Inst. 37:1960;351-361.
24. Hollander M., Wolfe D.A. The two-sample location problem. Nonparametric statistical methods. 1st edn:1973;67-82 John Wiley and sons, New York.
25. Pauwels R., Buist A., Calverley P., Jenkins C., Hurd S. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med. 163:2001;1256-1276.
26. Thompson A., Mueller M., Heires A., et al. Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation. Am Rev Respir Dis. 146:1992;389-395.
27. Wijkstra P., Ten Vergert E., Van Altena R., et al. Reliability and validity of the chronic respiratory questionnaire (CRQ). Thorax. 49:1994;465-467.
28. Rutten-van Molken M., Roos B., Van Noord J. An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. Thorax. 54:1999;995-1003.
29. Bestall J., Paul E., Garrod R., Garnham R., Jones P., Wedzicha J. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measurement of disability in patients with chronic obstructive pulmonary disease. Thorax. 54:1999;581-586.
30. Osman I., Godden D., Friend J., Legge J., Douglas J. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax. 52:1997;67-71.
31. Knox A., Zhu Y., Pang L. Do long-acting beta2-adrenoceptor agonists enhance the anti-inflammatory effect of glucocorticoids in asthma? Eur Respir J. 17:2001;1059-1061.
32. Dowson L., Newall C., Guest P., Hill S., Stockley R. Exercise capacity predicts health status in alpha(1)-antitrypsin deficiency. Am J Respir Crit Care Med. 163:2001;936-941.
33. Barnes P. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and oral corticosteroids. Eur Respir J. 19:2002;182-191.